Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
SARMEvidence Grade: B (Human Trials)
LGD-4033 (Ligandrol) Protocol Guide
LGD-4033 (Ligandrol) is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals for muscle wasting and osteoporosis. It selectively binds androgen receptors in muscle and bone tissue, promoting anabolic activity without the androgenic side effects of traditional steroids. This protocol covers oral dosing at 5-10mg daily, cycle length, PCT considerations, and bloodwork monitoring.
Protocol Overview
Compound
LGD-4033 (Ligandrol)
Category
Selective Androgen Receptor Modulator (SARM)
Mechanism
Selectively binds androgen receptors in skeletal muscle and bone, stimulating anabolic pathways (protein synthesis, nitrogen retention) with minimal activity in prostate and sebaceous glands
Half-Life
24-36 hours
Form
Oral liquid or capsule
Route
Oral
Frequency
Once daily
Cycle Length
8-12 weeks
Dosing Protocol
Protocol
Dose
Frequency
Route
Duration
Beginner
5 mg
1x daily
Oral
8 weeks
Intermediate
10 mg
1x daily
Oral
8-10 weeks
Advanced
10 mg
1x daily
Oral
10-12 weeks
Recomp
5-10 mg
1x daily
Oral
8-12 weeks
Expected Timeline
Week 1-2
Initial strength increases and improved muscle fullness. Mild suppression of natural testosterone may begin.
Week 3-4
Noticeable lean mass gains (2-4 lbs). Strength continues to increase across compound lifts. Some water retention possible.
Week 5-6
Peak anabolic effects. Continued muscle accrual. Suppression of endogenous testosterone becomes more pronounced.
Week 7-8
Gains plateau for some users. Lipid changes (HDL suppression) typically at their maximum. Good stopping point for beginners.
Week 9-12
Extended cycle for experienced users. Diminishing returns beyond week 10 for most. PCT should begin 24-36 hours after last dose.
Side Effects & Monitoring
Common Side Effects
Mild testosterone suppression (dose-dependent)
Headaches (transient, usually week 1)
Water retention / bloating
Mild fatigue toward end of cycle
Temporary HDL cholesterol reduction
Precautions
Requires PCT (post-cycle therapy) after 8+ week cycles
